Overview

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation